Guideline for Microalbuminuria Screening



Similar documents
Diabetic nephropathy is detected clinically by the presence of persistent microalbuminuria or proteinuria.

Chronic Kidney Disease (CKD) Algorithm. Chronic Kidney Disease (CKD) Algorithm Page 1

Diabetes and the Kidneys

Renal Disease in Type 2 Diabetes Mellitus

Understanding diabetes Do the recent trials help?

Calculating the stage of Renal Disease

Definition, Prevalence, Pathophysiology and Complications of CKD. JM Krzesinski CHU Liège-ULg Core curriculum Nephrology September 28 th 2013

Chronic Kidney Disease and the Electronic Health Record. Duaine Murphree, MD Sarah M. Thelen, MD

Chronic kidney disease frequently asked questions

Primary Care Management of Male Lower Urinary Tract Symptoms. Matthew B.K. Shaw Consultant Urological Surgeon

Diabetic Nephropathy

Microalbuminuria: We are in the midst of an epidemic: the epidemic. So What s a Little Protein? Malcolm s diabetes. How much is too much?

Southern Derbyshire Shared Care Pathology Guidelines. AKI guidelines for primary care

Cardiovascular Risk in Diabetes

Hypertension Guidelines

Identifying and treating long-term kidney problems (chronic kidney disease)

Southern Derbyshire Shared Care Pathology Guidelines. Hyperkalaemia

InDependent Diabetes Trust

SUMMARY OF CHANGES TO QOF 2015/16 - ENGLAND CLINICAL

GUIDELINES FOR THE TREATMENT OF DIABETIC NEPHROPATHY*

Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results

Chronic Kidney Disease

Kidney Disease: Key Facts and Figures. September 2010

ADULT HYPERTENSION PROTOCOL STANFORD COORDINATED CARE

Chronic Kidney Disease and Diabetes

Guidelines for the management of hypertension in patients with diabetes mellitus

CHRONIC KIDNEY DISEASE MANAGEMENT GUIDE

HYPERTENSION ASSOCIATED WITH RENAL DISEASES

Drug Treatment in Type 2 Diabetes with Hypertension

Coding to be more efficient and accurate

High Blood Pressure and Kidney Disease

PRESCRIBING GUIDELINES FOR LIPID LOWERING TREATMENTS for SECONDARY PREVENTION

In many diabetes units, people with type

GFR (Glomerular Filtration Rate) A Key to Understanding How Well Your Kidneys Are Working

DR. Trinh Thi Kim Hue

Diagnosis, classification and staging of chronic kidney disease

Dabigatran: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF

Prevalence and risk factor of chronic kidney disease in elderly diabetic patients in Korea 성애병원 내과 김정한

TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D.

Medicare s Preventive Care Services. Manage Your Chronic Kidney Disease (CKD stages 3-4) with Diet

Kidney Disease WHAT IS KIDNEY DISEASE? TESTS TO DETECT OR DIAGNOSE KIDNEY DISEASE TREATMENT STRATEGIES FOR KIDNEY DISEASE

CME Test for AMDA Clinical Practice Guideline. Diabetes Mellitus

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT of Atrial Fibrillation (AF)

DRUG UTILIZATION EVALUATION OF ANTIHYPERTENSIVE DRUGS IN DIABETIC PATIENTS WITH CKD

Electronic Health Record Strategies for Pay for Performance. James O Connor MD Director of Clinical Informatics

Renovascular Hypertension

NICE Pathways bring together all NICE guidance, quality standards and other NICE information on a specific topic.

Absolute cardiovascular disease risk management

Summary of QOF indicators

Rivaroxaban: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF

Rheumatoid Arthritis. GP workshop 15 January 2011

Absolute cardiovascular disease risk

G:\ CDM\BHCIG Diabetes Pathway FINAL September 05.doc 1

Registered Charity No: Caring for those with a rare, complex and lifelong disease

Open the Flood Gates Urinary Obstruction and Kidney Stones. Dr. Jeffrey Rosenberg Dr. Emilio Lastarria Dr. Richard Kasulke

Metabolic Syndrome Overview: Easy Living, Bitter Harvest. Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007

Advanced Clinical Decision Support & Acute Kidney Injury

CASE A1 Hypoglycemia in an Elderly T2DM Patient with Heart Failure

Blood in the Urine (Haematuria)

Hypertension Guideline V4

Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Diabetes sections of the Guidelines)

CASE B1. Newly Diagnosed T2DM in Patient with Prior MI

Clinical Quality Measure Crosswalk: HEDIS, Meaningful Use, PQRS, PCMH, Beacon, 10 SOW

Use of Glycated Hemoglobin and Microalbuminuria in the Monitoring of Diabetes Mellitus

POAC CLINICAL GUIDELINE

CDS Starter Kit: Diabetes f ollow-up care

Diagnostic Tests in Chronic Kidney Disease

Diabetic nephropathy is a major cause of morbidity and

ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes

Nierfunctiemeting en follow-up van chronisch nierlijden

PROCEEDINGS DIABETIC NEPHROPATHY: DETECTION AND TREATMENT OF RENAL DISEASE IN PATIENTS WITH DIABETES* Jiten Vora, MA, MD, FRCP ABSTRACT

John Sharp, MSSA, PMP Manager, Research Informatics Quantitative Health Sciences Cleveland Clinic, Cleveland, Ohio

1. What is the prostate-specific antigen (PSA) test?

Performance Measurement for the Medicare and Medicaid Eligible (MME) Population in Connecticut Survey Analysis

NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation

Care of the Catheterised Patient and Urinalysis

UTI in children. Quick reference guide. Issue date: August Urinary tract infection in children: diagnosis, treatment and long-term management

Absolute cardiovascular disease risk assessment

Diagnostic Assessments Relating to Renal Function: Why we do them? What do they mean? Mohamud Karim MD, FRCPC. Feb 27, 2015

How To Determine The Prevalence Of Microalbuminuria

Diabetes and Your Kidneys

Most probable Diagnosis

Nephrology (Renal Medicine)

Prediction of Kidney Disease Progression in Patients with Diabetes

NHS FORTH VALLEY Rivaroxaban for Stroke Prevention in Atrial Fibrillation

Tackling the Semantic Interoperability challenge

ECG may be indicated for patients with cardiovascular risk factors

Insulin is a hormone produced by the pancreas to control blood sugar. Diabetes can be caused by too little insulin, resistance to insulin, or both.

Treatment Recommendations for CKD in Cats (2015)

Diabetes in Primary Care course MCQ Answers 2016

Medical management of CHF: A New Class of Medication. Al Timothy, M.D. Cardiovascular Institute of the South

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD

Appendix D- Monoclonal Gammopathy of Undetermined Significance (MGUS)

Creatinine (serum, plasma)

The contribution of chronic kidney disease to the global burden of major noncommunicable diseases

MINISTRY OF HEALTH AND LONG-TERM CARE Primary Health Care Team FACT SHEET

HIGH BLOOD PRESSURE AND YOUR KIDNEYS

Management of High Blood Pressure in Adults Based on the Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC8)

High Blood Pressure and Chronic Kidney Disease

Managing diabetes in the post-guideline world. Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ)

Transcription:

East Lancashire Diabetes Network Guideline for Microalbuminuria Screening Produced by: Task and Finish Group, Clinical Standards Group Produced: August 2006 Approved by: East Lancashire Diabetes Network Clinical Standards Group August 2006 Guideline reviewed: February 2007 (CKD guidelines updated October 2007) Approved for use in: East Lancashire Primary Care Trust Blackburn with Darwen Primary Care Trust East Lancashire Hospitals NHS Trust

Microalbuminuria Screening Identification Guidelines To identify patients who would benefit from microalbuminuria testing Diabetic Patients aged 12 and over Is the patient already diagnosed with Proteinuria or Microalbuminuria? Should be coded:- C10EK Type 1 diabetes with persistent proteinuria C10EL persistent microalbuminuria C10FL Type 2 diabetes with persistent proteinuria C10FM persistent microalbuminuria (See your PRIMIS facilitator for help with validating this register) Are they being prescribed an ACE or AT II?* TEST but need to ensure they are being prescribed ACE or ATII* Microalbuminuria TEST (follow algorithm) Microalbuminuria TEST NB: ALL patients should continue to have annual Protein dipstick * One of the following codes should be added if ACE cannot be prescribed:- ACE Inhibitor Angiotensin II Contraindicated 8I28 8I2H Declined 8I3D 8I3P t indicated 8I64 8I6C t tolerated 8I74 8I75

MICROALBUMINURIA SCREENING Screening Strategy 12 years and over All patients with diabetes over 12 years should have their urine tested annually with a dipstick to identify level of protein Dipstick (ideally 1st morning mid-stream specimen) urine for protein- exclude the visual presence of blood. If Positive If Negative Consider & treat infection and confirm persistent proteinuria on 2 further clear catch samples Keep sample cool and send the sample promptly to path. lab for microalbumin/creatinine ratio, in white topped bottle If proteinuria confirmed, send urine sample to lab for protein/creatinine ratio refer to renal management pathway (attached) for diabetic nephropathy If Positive [male >2.5 mg/mmol] [female >3.5 mg/mmol] If Negative further action and repeat in 1 year NB - If retinopathy is not present and proteinuria/microalbuminuria confirmed, consider a non diabetic cause of renal disease and investigate as appropriate Send up to 2 further early morning clear catch specimens of urine within the next month Ideally, all people with diabetes should be screened as per national guidelines. The local Diabetes Network is working towards meeting the requirements of the national guidelines 2 out of 3 positive samples confirm microalbuminuria and refer to renal management pathway (see referral criteria attached). Feb 07 v4

LANCASHIRE TEACHING HOSPITALS NHS TRUST DEPARTMENT OF RENAL MEDICINE GUIDE FOR IDENTIFICATION, MANAGEMENT AND REFERRAL OF ADULTS WITH CHRONIC KIDNEY DISEASE 30/6/2007 (version 2.0) To be reviewed June 2008 1) This is a guide to the management and referral of adult patients with chronic kidney disease. Reduction of Kidney Function is common, particularly in the elderly and most patients can be treated in primary care. Acute Renal Failure warrants urgent referral. 2) Cardiovascular complications are the main cause of mortality and morbidity. This is much more common than end-stage renal failure. Reduction of cardiovascular risk is the most important aspect of treatment. 3) Estimated GFR (egfr) should be calculated from blood using the abbreviated MDRD formulae. Local laboratories will provide this on patients with a significant elevation of plasma creatinine or on request. There is no need for 24 hour urine collections. 4) Reduced kidney function is defined as GFR <60ml/min or 60-90 ml/min in patients with other evidence of kidney disease. A system for staging is provided. 5) GFR > 60 ml/min is considered normal unless there is a second reason to suspect renal disease. 6) Some loss of kidney function is common with ageing. On average GFR falls by 1 ml/min each year after age 40. Referral should take into account age and co-morbidity. 7) Proteinuria indicates kidney disease. This can be estimated from protein-creatinine ratio measured in a single random urine sample (preferably early morning). 8) Macroscopic and microscopic haematuria may indicate intrinsic kidney disease. Refer all patients with macroscopic haematuria and those over age 50 with microscopic haematuria to Urology under 2 week rule. Check renal function in all patients and refer to Nephrology if this is abnormal or there is proteinuria. 9) The use of ACE inhibitors and ARBs often causes concern. The benefits outweigh risks in most patients (see notes) and are dose - related. Use the highest tolerated dose. Reserve ARBs for patients who get side-effects from ACE Inhibitors.

Summary Hypertension, Diabetes, Coronary heart Disease, Heart Failure, Atherosclerosis, Family History of kidney disease. Suspect Chronic Kidney Disease EGFR Read code 415E Check BP & test urine for protein and blood Send blood for egfr Is the patient acutely unwell? Symptoms of outflow obstruction? Poor Flow, Frequency, cturia, Elderly Men If normal Manage illness as appropriate. Repeat GFR within 1-7 days Palpate for bladder Consider renal tract ultrasound Has a reduced GFR/raised creatinine been measured previously? Repeat GFR GFR > 60ml/min and other evidence of kidney damage GFR <30 ml/min Renal ultrasound scan if history suggestive of urological disease GFR <60ml/min Give smoking and weight advice Treat BP with target <130/80 (<125/75 if proteinuria). Use ACE Inhibitor (ARB if side-effects) if proteinuria, micro-albuminuria or heart failure. Consider recommending that patients buys own meter. This must be validated by British Hypertension Society Treat hyperlipidaemia Aspirin if 10 year CV risk > 15% Avoid NSAID Influenza/Pneumococcal vaccination if GFR < 60 ml/min If urine protein > + and negative for nitrites or leucocytes, send a random urine for protein/creatinine ratio. Refer to renal team if PCR > 100 mg/mmol or if PCR > 50 mg/mmol and dipstick is > + for blood. Recheck egfr at 6 12 months. If rate of decline > 4ml/min per year, refer to or discuss with nephrologist Refer or, if not for active treatment, discuss with Nephrologist (based on co-morbidity/extrarenal disease). Shared Care. NB: Blood pressure control is very important. This may take a very long time unless patients are seen frequently until the best possible control has been achieved.

Testing urine for protein By dipstick (NB there is no need for 24hr urine collection at any stage) There is no evidence that asymptomatic urine infection causes proteinuria If positive(1+ or more): a) send a urine sample to Clinical Chemistry for protein/creatinine ratio (PCR). If PCR > 30mg/mmol, repeat on early morning urine (first sample on getting up; because protein may be absent after recumbency) b) test for blood using dipstick c) estimate GFR from serum creatinine N.B. Patients with diabetes mellitus should have annual testing for microalbuminuria (urine albumin/creatinine ratio, ACR) only if dipstick protein negative. ACR is a more sensitive and expensive test and not necessary for patients who are not diabetic or diabetic patients who are already taking an ACE Inhibitor or ARB (see diabetes guideline), for whom testing with a standard stick is adequate. Testing urine for blood By dipstick (NB there is no need for urine microscopy) If positive (1+ or more) a) exclude infection, menstruation, trauma b) test for urine protein (see above) c) estimate GFR (as above) Microscopic haematuria is common. Progressive renal disease is rare in the absence of proteinuria, other evidence of kidney disease or +++ of blood. Isolated microscopic haematuria (+ or ++) can be monitored in primary care after excluding urological disease. Urology guidelines require MSSU, renal ultrasound and plain abdominal x-ray at all ages and flexible cystoscopy for those over age 50. Staging of Kidney Disease GFR Minimum Stage ml/min testing 1* rmal GFR* >90 annually 2* Slight impairment* 60-89 annually 3A Mild impairment 45-59 annually 3B Moderate impairment 30-44 6-monthly 4 Severe impairment 15-29 3-monthly 5 Established renal failure <15 3-monthly *The terms stages 1 and 2 apply only when there is a structural abnormality such as polycystic kidney disease or a functional abnormality such as persistent proteinuria. Otherwise a GFR of 60-89 is considered normal. The suffix p may be added when there is proteinuria (PCR >100 mg/mmol), i.e. 2p means stage 2 with proteinuria

MONITORING OF CHRONIC KIDNEY DISEASE Estimated GFR 30-60 ml/min or other evidence of kidney disease (Stage 1-3 CKD) Parameter Stages 1, 2 and 3A Stage 3B and all Patients with Proteinuria (PCR >100 mg/mmol) Creatinine and Every 12 months Every six months potassium Haemoglobin If clinically indicated Every six months Dipstick Test for Every 12 months Proteinuria (or Urine PCR if positive ++ or more) Meticulous control of blood pressure The threshold for initiation of treatment is 140/90 or 130/80 for those with urine PCR > 100 mg/mmol; target BP 130/80 if PCR < 100 or 125/75 for those with urine PCR > 100 mg/mmol. See hypertension guideline for advice on treatment of blood pressure.. Anaemia should be investigated to exclude iron deficiency and other common causes. After these have been excluded refer to renal physician if Hb <10.5 g/dl. Abnormal corrected calcium or phosphate concentrations are indications for referral. Estimated GFR < 30 ml/min (Stages 4 and 5 CKD) Patients with stage 4 or 5 CKD should be referred to a nephrologist (see Referral Information). Exceptions include patients with a terminal illness, those who have already been investigated and for whom further investigation and management is inappropriate. Parameter Creatinine, potassium & bicarbonate Haemoglobin Calcium Every 3 months Every 3 months Every 6 months Monitoring kidney function when prescribing ACEI or ARB ACE Inhibitors and ARBs are indicated for patients with proteinuria, diabetic microalbuminuria, left ventricular dysfunction and other evidence of vascular disease. They may be used in patients with reduced kidney function. Benefits have been demonstrated up to a creatinine of 500 micromole/l. Serum creatinine and potassium concentrations should be checked prior to starting ACEI and/or ARBs, within 2 weeks of starting or increasing dose; and at annual intervals thereafter, or more frequently if indicated, according to kidney function. A rise of serum creatinine concentration of > 30 % or fall in estimated GFR of > 25% after initiation or dose increase should prompt referral to a nephrologist. If serum K+ > 6.0 mmol/l, repeat blood sample, to exclude haemolysis. If confirmed check diet (to exclude LoSalt), stop concomitant nephrotoxic drugs (e.g. NSAIDs), reduce or stop potassium-retaining diuretics (amiloride, triamterene, spironolactone). Metformin Metformin is excreted by the kidneys and may accumulate in renal failure. It is contraindicated in advanced renal failure, although the risk is small. Consider alternative treatment when egfr < 30 ml/min.

REFERRAL Urgent Rapidly deteriorating kidney function/suspected acute renal failure. Newly detected GFR < 15 ml/min with symptoms (Stage 5 CKD). Accelerated or malignant phase hypertension. Severe hyperkalaemia (serum potassium > 7 mmol/l) Nephrotic syndrome Multisystem disease (e.g. SLE) with evidence of kidney disease (i.e. abnormal GFR, proteinuria or haematuria). Routine Newly detected GFR < 30 ml/min (Stage 4 and 5 CKD) after consideration of age and co-morbidity. Proteinuria with urine protein:creatinine ratio (PCR) > 100 mg/mmol (irrespective of GFR) Rise in serum creatinine > 15% or fall in GFR > 4 ml/min over 12 months after confirmation with a second blood test. Acute deterioration in kidney function associated with use of ACEIs or ARBs (defined as a fall of GFR of >25% or 30% rise in serum creatinine concentration from pre-treatment level or level prior to latest increase in dosage). Haematuria + proteinuria (> 50 mg/mmol) (irrespective of GFR) Urologically unexplained macroscopic haematuria. (Macroscopic haematuria should be referred under 2 week rule to Urology for cystoscopy) Refractory hypertension (inadequate BP control, defined as BP > 150/90 mm Hg despite 4 drug combination therapy) plus suspicion of underlying kidney disease Anaemia (Hb <10.5g/dL) after exclusion of other causes of anaemia. Hyperkalaemia (serum potassium > 6.0 mmol/l on more than one sample) after exclusion of artefactual and treatable causes. Abnormal calcium or phosphate concentrations in patients with kidney disease. Referral Information Main kidney problem & how discovered Past medical and drug history Social circumstances Current and past Blood Pressure measurements and treatment Relevant physical examination e.g palpable bladder. List of dates and results of serum creatinine to assess stability Dipstick results and protein-creatinine ratio if positive Result of renal ultrasound scan. Further Advice http://www.renal.org/ckdguide/ckd.html A secure email helpline from the Preston Renal Unit will be available soon.